Phibro Animal Health Corporation to Participate in Stifel Jaws & Paws Conference
Business Wire (Thu, 21-May 4:30 PM ET)
Phibro Animal Health Corporation to Participate in Bank of America Securities Health Care Conference
Business Wire (Thu, 7-May 4:30 PM ET)
Phibro Animal Health Corporation Reports Third Quarter Results, Updates Financial Guidance
Business Wire (Wed, 6-May 4:30 PM ET)
Phibro Animal Health Corporation Declares Quarterly Dividend
Business Wire (Tue, 5-May 4:30 PM ET)
Business Wire (Tue, 5-May 4:15 PM ET)
Phibro Animal Health Corporation to Host Webcast and Conference Call on Third Quarter Results
Business Wire (Wed, 29-Apr 4:30 PM ET)
Phibro Animal Health Corporation Announces Regulatory Framework Change in Brazil for Antimicrobials
Business Wire (Mon, 27-Apr 4:30 PM ET)
Market Chameleon (Fri, 19-Dec 3:42 AM ET)
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
Phibro Animal Health - Class A trades on the NASDAQ stock market under the symbol PAHC.
As of July 24, 2026, PAHC stock price climbed to $34.15 with 69,547 million shares trading.
PAHC has a beta of 0.11, meaning it tends to be less sensitive to market movements. PAHC has a correlation of 0.00 to the broad based SPY ETF.
PAHC has a market cap of $1.39 billion. This is considered a Small Cap stock.
Last quarter Phibro Animal Health - Class A reported $384 million in Revenue and $.76 earnings per share. This beat revenue expectation by $18 million and exceeded earnings estimates by $.05.
In the last 3 years, PAHC traded as high as $60.08 and as low as $9.40.
The top ETF exchange traded funds that PAHC belongs to (by Net Assets): IJR, VTI, IWM, VXF, SPSM.
PAHC has underperformed the market in the last year with a return of +16.2%, while the SPY ETF gained +17.6%. In the last 3 month period, PAHC fell short of the market, returning -37.3%, while SPY returned +4.5%. However, in the most recent 2 weeks PAHC has outperformed the stock market by returning +5.5%, while SPY returned -1.8%.
PAHC support price is $33.13 and resistance is $34.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PAHC shares will trade within this expected range on the day.